Jennison Associates LLC Makes New Investment in Sotera Health Company $SHC

Key Points

• Jennison Associates LLC acquired a new position of 1,401,362 shares of Sotera Health (NASDAQ:SHC) in Q4, worth about $24.72 million and representing roughly 0.49% of the company.
• Director GTCR Investment XI LLC sold 10,000,000 shares on March 6 at an average price of $15.27 for approximately $152.7 million, reducing its ownership by 43.98%; insiders still own 15.36% of the stock.
• Sotera Health beat estimates with $0.26 EPS (vs. $0.24 expected) and $303.44M revenue for the quarter, set FY2026 guidance of $0.93–1.01 EPS (analysts expect ~0.88), and the stock trades with a $4.44B market cap and a P/E of ~57.6.

Jennison Associates LLC acquired a new position in Sotera Health Company (NASDAQ:SHC - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,401,362 shares of the company's stock, valued at approximately $24,720,000. Jennison Associates LLC owned approximately 0.49% of Sotera Health at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. True Wealth Design LLC increased its stake in shares of Sotera Health by 389.3% in the fourth quarter. True Wealth Design LLC now owns 1,830 shares of the company's stock worth $32,000 after purchasing an additional 1,456 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Sotera Health by 117.6% in the third quarter. Versant Capital Management Inc now owns 2,535 shares of the company's stock worth $40,000 after purchasing an additional 1,370 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Sotera Health by 831.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company's stock worth $37,000 after purchasing an additional 2,935 shares in the last quarter. Fairway Wealth LLC purchased a new stake in shares of Sotera Health in the third quarter worth $57,000. Finally, GAMMA Investing LLC increased its stake in shares of Sotera Health by 31.1% in the fourth quarter. GAMMA Investing LLC now owns 4,892 shares of the company's stock worth $86,000 after purchasing an additional 1,161 shares in the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $15.27, for a total transaction of $152,700,000.00. Following the completion of the transaction, the director owned 12,735,301 shares in the company, valued at $194,468,046.27. This trade represents a 43.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.36% of the stock is owned by company insiders.

Sotera Health Price Performance

SHC stock opened at $15.56 on Friday. Sotera Health Company has a 52 week low of $10.80 and a 52 week high of $19.85. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 3.66. The company has a fifty day simple moving average of $15.04 and a two-hundred day simple moving average of $16.48. The firm has a market capitalization of $4.44 billion, a P/E ratio of 57.61 and a beta of 1.82.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. Sotera Health had a net margin of 6.70% and a return on equity of 42.38%. The business had revenue of $303.44 million during the quarter, compared to analyst estimates of $300.68 million. During the same quarter last year, the business earned $0.21 earnings per share. Sotera Health's quarterly revenue was up 4.6% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. Analysts anticipate that Sotera Health Company will post 0.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

SHC has been the subject of a number of analyst reports. Royal Bank Of Canada initiated coverage on shares of Sotera Health in a research note on Thursday, January 8th. They issued an "outperform" rating and a $24.00 price objective for the company. Citigroup increased their price objective on shares of Sotera Health from $21.00 to $23.00 and gave the stock a "buy" rating in a research note on Tuesday, February 24th. Wells Fargo & Company cut shares of Sotera Health to an "overweight" rating in a research note on Thursday, January 8th. Piper Sandler raised shares of Sotera Health from a "neutral" rating to an "overweight" rating and raised their target price for the company from $17.00 to $24.00 in a research note on Friday, January 9th. Finally, Wall Street Zen cut shares of Sotera Health from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 11th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $20.14.

About Sotera Health

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.